Table 2 Effect of SGLT2i in clinical treatment
From: Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Drugs | Type | Object | Follow-up period | Effect of outcome |
|---|---|---|---|---|
Multiple SGLT2i | Clinical trial | 77 first heart transplant recipients (37 patients with diabetes) | At least 6Â months before surgery and 12Â months after surgery | Reduce myocardial triglyceride accumulation [1] |
Empagliflozin | Randomized controlled trial | 97 participants with T2DM and coronary artery disease (CAD) | 6Â months | Reduce LVM indexed to body surface area [2] |
Dapagliflozin | Randomized controlled trial | 66 patients with T2DM and LVH | 12Â months | Reduce absolute LVM [3] |
Dapagliflozin | Randomized controlled trial | 97 patients with T2DM and atherosclerotic disease | 12Â weeks | Increase FMD [4] |
Dapagliflozin | Randomized controlled trial | 16 patients with T2DM and stable coronary artery disease | 4Â weeks | Increase MFR [5] |
Dapagliflozin | Clinical trial | 59 patients with T2DM | 6Â weeks | Improve vascular remodelling [6] |
Multiple SGLT2i | Observational study | 583 diabetic AMI patients treated with percutaneous coronary intervention (PCI) | The use of SGLT2i started at least 3Â months before hospitalization | Reduce infarct size after AMI [7] |
Empagliflozin | Clinical trial | 1549 patients with T2DM | 104Â weeks | Reduce blood uric acid concentration [8] |
Dapagliflozin | Clinical trial | 3119 patients with heart failure | 12Â months | Reduce blood uric acid concentration [9] |
Canagliflozin | Clinical trial | 2313 patients with T2DM | 26Â weeks | Reduce blood uric acid concentration [10] |
Dapagliflozin | Randomized controlled trial | 44 patients with T2DM | 12Â weeks | Did not change the composition of the gut flora [11] |
Multiple SGLT2i | Meta-analysis | 38,335 patients with type 2 diabetes | Median follow-up duration was 1.8Â years | Reduce the risk of AF and AFL [12] |
Multiple SGLT2i | Meta-analysis | 1831 patients with acute heart failure with and without T2DM | Ranged from 60Â days to 9Â months | Reduce the risk of rehospitalization for heart failure and improve KCCQ score [13] |
Multiple SGLT2i | Meta-analysis | 10978 patients with T2DM with or without chronic heart failure | Ranged from 14Â days to 1Â year | Reduce NT-proBNP concentrations and improve cardiac diastolic function and LVEF [14] |